For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. | ...
Total product sales -- $7.3 billion in fiscal Q3 2025, up 4% sequentially from Q2 2025, with growth driven by the HIV ...
Investor's Business Daily on MSN
Gilead Sciences Dives As HIV Drug Misses Bullish Buy-Side Expectations
Gilead stock slumped late Thursday on soft product sales and lighter-than-expected revenue from its newcomer HIV prevention ...
Southern Eye on MSN
Digital hope: How CATS programme is transforming HIV care for adolescents in Gutu
Dzidzai is one of 25 Community Adolescent Treatment Supporters (CATS) trained by the National Aids Council (NAC) and the ...
Elimination isn’t just about having the tools. It’s about deploying them equitably and sustainably,” says expert.
Ten years ago, the Indiana community of Austin made headlines for its historic HIV outbreak brought on by intravenous drug ...
News-Medical.Net on MSN
Improving tobacco cessation care for people living with HIV
People living with HIV who smoke are currently more likely to die from lung cancer than from HIV-related causes. Two cancer ...
Cancer patients who got an mRNA COVID vaccine within a few months of their immunotherapy lived longer than those who did not, health records show.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback